Google
UNCY — UNICYCIVE THERAPEUTICS INC (Healthcare >> Biotechnology)
UNCY FAQ
What is UNCY's ROE?
UNICYCIVE THERAPEUTICS INC reports a Return on Equity (ROE) of -105.95%.
What is UNCY's dividend yield?
UNICYCIVE THERAPEUTICS INC offers a dividend yield of 0.00%.
What is UNCY's Deepscope Quality Score?
Deepscope rates UNCY's overall financial quality at 31 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy UNCY?
Deepscope's AI Timing Score for UNCY is 70 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does UNCY belong to?
UNICYCIVE THERAPEUTICS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 7.43
Price
0.23
(3.19%)
Day Change
|
|
|---|
UNCY, the overall quality is not good ( Quality = 31) but the timing to buy is ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROE is relatively low.
ROA is relatively low.
Acceleration of ROE growth rate is below our criteria.
ROE is decreasing significantly
Acceleration of ROA growth rate is below our criteria.
Current growth of ROA was below our criteria.
Net profit margin is relatively low.
Acceleration of net profit margin growth rate is below our criteria
Historical net profit margin is relatively low.
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Quality Factors |
|
42% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 96 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 7.43 |
| PBV / Sector |
5.12 / 4.58
|
| Earning Per Share | -1.54 |
| PE / Sector |
N/A / 17.10
|
| PEG or PE/Growth / Sector |
N/A / 0.52
|
| Average 1M Daily Value |
5.23 M
GREAT
|
| Average 1W Daily Value |
5.34 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| Ability to Make Profit |
|
47% |
| Return to Investors |
|
4% |
| Registration Details |
| Analyze Date | 2026-06-05 09:12:00 |
| Symbol | UNCY |
| Name | UNICYCIVE THERAPEUTICS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 26.70 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 193.04 / 8,655.90 |
| News, Concensus, ... |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1975 West El Camino Real, Mountain View, CA, United States, 94040
Phone: 650 351 4495
Website: https://unicycive.com
Sector: Healthcare >> Biotechnology
Description: Unicycive Therapeutics, Inc., a clinical-stage biotechnology company, identifies, develops, and commercializes therapies for the treatment of kidney diseases in the United States. It develops oxylanthanum carbonate, a lanthanum-based phosphate binding agent, which is for the treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI-494, a nicotinamide ester derivative and a selective ATP-sensitive mitochondrial potassium channel activator, which is in Phase I clinical trial for the treatment of acute kidney injury and pre-clinical stage for the treatment of chronic kidney disease. The company was incorporated in 2016 and is headquartered in Mountain View, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
